Evidence map›Paper›PMID 33322104›Full record

ArticleMolecules (Basel, Switzerland)2020

In Vivo Targeted Metabolomic Profiling of Prostanit, a Novel Anti-PAD NO-Donating Alprostadil-Based Drug.

Ksenia M Shestakova, Natalia E Moskaleva, Natalia V Mesonzhnik, Alexey V Kukharenko, Igor V Serkov, Igor I Lyubimov, Elena V Fomina-Ageeva, Vladimir V Bezuglov, Mikhail G Akimov, Svetlana A Appolonova

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Ksenia M ShestakovaLaboratory of Pharmacokinetics and Metabolomic Analysis, Institute of Translational Medicine and Biotechnology, I.M. Sechenov First Moscow State Medical University, 2-4 Bolshaya Pirogovskaya St., 119991 Moscow, Russia.
Natalia E MoskalevaLaboratory of Pharmacokinetics and Metabolomic Analysis, Institute of Translational Medicine and Biotechnology, I.M. Sechenov First Moscow State Medical University, 2-4 Bolshaya Pirogovskaya St., 119991 Moscow, Russia.
Natalia V MesonzhnikLaboratory of Pharmacokinetics and Metabolomic Analysis, Institute of Translational Medicine and Biotechnology, I.M. Sechenov First Moscow State Medical University, 2-4 Bolshaya Pirogovskaya St., 119991 Moscow, Russia.
Alexey V KukharenkoLaboratory of Pharmacokinetics and Metabolomic Analysis, Institute of Translational Medicine and Biotechnology, I.M. Sechenov First Moscow State Medical University, 2-4 Bolshaya Pirogovskaya St., 119991 Moscow, Russia.
Igor V SerkovInstitute of Physiologically Active Compounds RAS, Severniy pr., 1, 142432 Chernogolovka, Russia.
Igor I LyubimovTerritory of Skolkovo Innovation Center, LLC "Gurus BioPharm", Bolshoy Boulevard, 42 Building 1, 143026 Moscow, Russia.
Elena V Fomina-AgeevaShemyakin-Ovchinnikov Institute of Bioorganic Chemistry RAS, St. Miklukho-Maklaya, 16/10, 117997 Moscow, Russia.
Vladimir V BezuglovShemyakin-Ovchinnikov Institute of Bioorganic Chemistry RAS, St. Miklukho-Maklaya, 16/10, 117997 Moscow, Russia.ORCID 0000-0001-8439-8607
Mikhail G AkimovShemyakin-Ovchinnikov Institute of Bioorganic Chemistry RAS, St. Miklukho-Maklaya, 16/10, 117997 Moscow, Russia.ORCID 0000-0002-7467-4409
Svetlana A AppolonovaLaboratory of Pharmacokinetics and Metabolomic Analysis, Institute of Translational Medicine and Biotechnology, I.M. Sechenov First Moscow State Medical University, 2-4 Bolshaya Pirogovskaya St., 119991 Moscow, Russia.
Sechenov University · RUInstitute of Bioorganic Chemistry · RUInstitute of Physiologically Active Compounds · RUSkolkovo Foundation · RU

Funding

Ministry of Science and Higher Education of the Russian Federation 14.N08.11.0119Sechenov University Research Foundation (no number)
6 · The paper itself

Abstract

Prostanit is a novel drug developed for the treatment of peripheral arterial diseases. It consists of a prostaglandin E

Indexed as

MetabolomicsAlprostadilAnimalsAnti-Inflammatory Agents, Non-SteroidalAortaChromatography, LiquidHumansMass SpectrometryMetabolic Networks and PathwaysMyocytes, Smooth MuscleNitric OxidePeripheral Arterial DiseaseRabbits15-ketoprostaglandin EAlprostadilAnti-Inflammatory Agents, Non-SteroidalNitric Oxide1,3-dinitroglycerolnitric oxide generationperipheral arterial diseaseProstanit metabolomic responseProstanit pharmacokinetics

Identifiers

PMID33322104
PMCPMC7764275
OpenAlexW3111764888

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.